BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 23953409)

  • 1. Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells.
    Sørensen BS; Busk M; Olthof N; Speel EJ; Horsman MR; Alsner J; Overgaard J
    Radiother Oncol; 2013 Sep; 108(3):500-5. PubMed ID: 23953409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer.
    Lassen P; Eriksen JG; Hamilton-Dutoit S; Tramm T; Alsner J; Overgaard J;
    Radiother Oncol; 2010 Jan; 94(1):30-5. PubMed ID: 19910068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of radiation on cell proliferation and tumor hypoxia in HPV-positive head and neck cancer in vivo models.
    Sørensen BS; Busk M; Horsman MR; Alsner J; Overgaard J; Kyle AH; Minchinton AI
    Anticancer Res; 2014 Nov; 34(11):6297-304. PubMed ID: 25368228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity.
    Rieckmann T; Tribius S; Grob TJ; Meyer F; Busch CJ; Petersen C; Dikomey E; Kriegs M
    Radiother Oncol; 2013 May; 107(2):242-6. PubMed ID: 23602369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck.
    Toustrup K; Sørensen BS; Lassen P; Wiuf C; Alsner J; Overgaard J;
    Radiother Oncol; 2012 Jan; 102(1):122-9. PubMed ID: 21996521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of CDK4/CDK6 Enhances Radiosensitivity of HPV Negative Head and Neck Squamous Cell Carcinomas.
    Göttgens EL; Bussink J; Leszczynska KB; Peters H; Span PN; Hammond EM
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):548-558. PubMed ID: 31271827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes.
    Foy JP; Bazire L; Ortiz-Cuaran S; Deneuve S; Kielbassa J; Thomas E; Viari A; Puisieux A; Goudot P; Bertolus C; Foray N; Kirova Y; Verrelle P; Saintigny P
    BMC Med; 2017 Sep; 15(1):165. PubMed ID: 28859688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial.
    Lassen P; Eriksen JG; Krogdahl A; Therkildsen MH; Ulhøi BP; Overgaard M; Specht L; Andersen E; Johansen J; Andersen LJ; Grau C; Overgaard J;
    Radiother Oncol; 2011 Jul; 100(1):49-55. PubMed ID: 21429609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRIP12 as a mediator of human papillomavirus/p16-related radiation enhancement effects.
    Wang L; Zhang P; Molkentine DP; Chen C; Molkentine JM; Piao H; Raju U; Zhang J; Valdecanas DR; Tailor RC; Thames HD; Buchholz TA; Chen J; Ma L; Mason KA; Ang KK; Meyn RE; Skinner HD
    Oncogene; 2017 Feb; 36(6):820-828. PubMed ID: 27425591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study.
    Eriksen JG; Overgaard J;
    Radiother Oncol; 2007 Jun; 83(3):383-8. PubMed ID: 17543403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials.
    Toustrup K; Sørensen BS; Metwally MA; Tramm T; Mortensen LS; Overgaard J; Alsner J
    Acta Oncol; 2016; 55(9-10):1091-1098. PubMed ID: 27161763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AKT inhibition as a strategy for targeting hypoxic HPV-positive HNSCC.
    Göttgens EL; Bussink J; Ansems M; Hammond EM; Span PN
    Radiother Oncol; 2020 Aug; 149():1-7. PubMed ID: 32361013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation-Induced Dedifferentiation of Head and Neck Cancer Cells Into Cancer Stem Cells Depends on Human Papillomavirus Status.
    Vlashi E; Chen AM; Boyrie S; Yu G; Nguyen A; Brower PA; Hess CB; Pajonk F
    Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1198-206. PubMed ID: 27026319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPV-positive HNSCC cell lines but not primary human fibroblasts are radiosensitized by the inhibition of Chk1.
    Busch CJ; Kriegs M; Laban S; Tribius S; Knecht R; Petersen C; Dikomey E; Rieckmann T
    Radiother Oncol; 2013 Sep; 108(3):495-9. PubMed ID: 23932155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inhibition of PARP but not EGFR results in the radiosensitization of HPV/p16-positive HNSCC cell lines.
    Güster JD; Weissleder SV; Busch CJ; Kriegs M; Petersen C; Knecht R; Dikomey E; Rieckmann T
    Radiother Oncol; 2014 Dec; 113(3):345-51. PubMed ID: 25467050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma.
    Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Iqbal K; Prasad R; Grau C; Overgaard J
    Radiother Oncol; 2015 Jul; 116(1):15-20. PubMed ID: 25913070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
    Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
    Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial.
    Overgaard J; Eriksen JG; Nordsmark M; Alsner J; Horsman MR;
    Lancet Oncol; 2005 Oct; 6(10):757-64. PubMed ID: 16198981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy With Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIMRAD).
    Thomson DJ; Slevin NJ; Baines H; Betts G; Bolton S; Evans M; Garcez K; Irlam J; Lee L; Melillo N; Mistry H; More E; Nutting C; Price JM; Schipani S; Sen M; Yang H; West CM;
    Int J Radiat Oncol Biol Phys; 2024 Jul; 119(3):771-782. PubMed ID: 38072326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological basis for increased sensitivity to radiation therapy in HPV-positive head and neck cancers.
    Bol V; Grégoire V
    Biomed Res Int; 2014; 2014():696028. PubMed ID: 24804233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.